PENTIXAPHARM HOLDING N AG (XETRA:PTP) — Market Cap & Net Worth
Market Cap & Net Worth: PENTIXAPHARM HOLDING N AG (PTP)
PENTIXAPHARM HOLDING N AG (XETRA:PTP) has a market capitalization of $46.89 Million (€40.11 Million) as of September 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #22232 globally and #1950 in its home market, demonstrating a 2.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PENTIXAPHARM HOLDING N AG's stock price €1.90 by its total outstanding shares 24783048 (24.78 Million).
PENTIXAPHARM HOLDING N AG Market Cap History: 2024 to 2026
PENTIXAPHARM HOLDING N AG's market capitalization history from 2024 to 2026. Data shows change from $85.47 Million to $55.05 Million (-35.16% CAGR).
PENTIXAPHARM HOLDING N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PENTIXAPHARM HOLDING N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest PENTIXAPHARM HOLDING N AG stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTP by Market Capitalization
Companies near PENTIXAPHARM HOLDING N AG in the global market cap rankings as of September 19, 2026.
Key companies related to PENTIXAPHARM HOLDING N AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
PENTIXAPHARM HOLDING N AG Historical Marketcap From 2024 to 2026
Between 2024 and today, PENTIXAPHARM HOLDING N AG's market cap moved from $85.47 Million to $ 55.05 Million, with a yearly change of -35.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €55.05 Million | +28.21% |
| 2025 | €42.94 Million | -49.76% |
| 2024 | €85.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of PENTIXAPHARM HOLDING N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.89 Million USD |
| MoneyControl | $46.89 Million USD |
| MarketWatch | $46.89 Million USD |
| marketcap.company | $46.89 Million USD |
| Reuters | $46.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more